首页> 外文期刊>International Journal of Pharmaceutics >Targeting prostate cancer cells with genetically engineered polypeptide-based micelles displaying gastrin-releasing peptide
【24h】

Targeting prostate cancer cells with genetically engineered polypeptide-based micelles displaying gastrin-releasing peptide

机译:靶向前列腺癌细胞与基于基于基于基于基于多肽的胶束,显示胃泌素释放肽

获取原文
获取原文并翻译 | 示例
           

摘要

In recent years G protein-coupled receptors (GPCRs) have emerged as crucial tumorigenic factors that drive aberrant cancer growth, metastasis and angiogenesis. Consequently, a number of GPCRs are strongly expressed in cancer derived cell lines and tissue samples. Therefore a rational anti-cancer strategy is the design of nano-medicines that specifically target GPCRs to bind and internalise cytotoxic drugs into cancer cells. Herein, we report the genetic engineering of a self-assembling nanoparticle based on elastin-like polypeptide (ELP), which has been fused with gastrin releasing peptide (GRP). These nanoparticles increased intracellular calcium concentrations when added to GRP receptor positive PC-3 prostate cancer cells, demonstrating specific receptor activation. Moreover, GRP-displaying fluorescent labelled nanoparticles showed specific cell-surface interaction with PC-3 prostate cancer cells and increased endocytic uptake. These nanoparticles therefore provide a targeted molecular carrier system for evaluating the delivery of cytotoxic drugs into cancer cells. (C) 2016 Elsevier B.V. All rights reserved.
机译:近年来,G蛋白偶联受体(GPCR)被出现为推动异常癌症生长,转移和血管生成的至关重要的致瘤因子。因此,在癌细胞系和组织样品中强烈表达了许多GPCR。因此,理性的抗癌策略是纳米药物的设计,具体靶向GPCR,将细胞毒性药物结合和内化为癌细胞。在此,我们报告了基于弹性蛋白样多肽(ELP)的自组装纳米粒子的基因工程,其与胃泌素释放肽(GRP)融合。当加入GRP受体阳性PC-3前列腺癌细胞时,这些纳米颗粒增加了细胞内钙浓度,证明了特异性受体激活。此外,GRP显示荧光标记的纳米颗粒显示出与PC-3前列腺癌细胞的特异性细胞表面相互作用和增加的内吞吸收。因此,这些纳米颗粒提供了靶向分子载体系统,用于评估将细胞毒性药物递送到癌细胞中。 (c)2016 Elsevier B.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号